Table 2.

Two-Way Repeated Measures ANOVA for DPOAEs (Subject Group vs. Time)

5–15kHz
F time (4,112) = 5.267	p = 0.0006
Bonferroni Post-test	Pre vs. 2 Mon	Pre vs. 3 Mon	Pre vs. 4 Mon
E	ns	ns	ns
E+P	ns	ns	t=2.872, p< 0.05
Placebo	ns	ns	ns
Male	ns	t=2.836, p< 0.05	t=2.562, p< 0.05

15–30kHz
F time (4,112) =14.81	p < 0.0001
Bonferroni Post-test	Pre vs. 2 Mon	Pre vs. 3 Mon	Pre vs. 4 Mon
E	ns	ns	ns
E+P	t=3.104, p<0.01	t=5.057, p<0.001	t=6.496, p<0.001
Placebo	ns	ns	t=2.717, p<0.005
Male	ns	t=2.759, p<0.05	ns
Bonferroni Post-test	1 Mon vs. 3 Mon	1 Mon vs. 4 Mon	2 Mon vs. 4 Mon
E	ns	ns	ns
E+P	t=3.930, p<0.001	t=5.369, p<0.001	t=3.392, p<0.01
Placebo	ns	ns	ns
Male	ns	ns	ns

30–45kHz
F time (4,112) =4.687	p = 0.0016
Bonferroni Post-test	Pre vs. 2Mon	Pre vs. 3 Mon	Pre vs. 4 Mon
E	ns	ns	ns
E+P	t=3.862, p<0.001	t=5.088, p<0.001	t=6.408, p<0.001
Placebo	ns	ns	ns
Male	ns	ns	ns
Bonferroni Post-test	1 Mon vs. 2 Mon	1 Mon vs. 3 Mon	1 Mon vs. 4 Mon
E	ns	ns	ns
E+P	t=3.494, p<0.01	t=4.720, p<0.001	t=6.039, p<0.001
Placebo	ns	ns	ns
Male	ns	ns	ns
Bonferroni Post-test	2 Mon vs. 4 Mon
E	ns
E+P	t=2.545, p<0.05
Placebo	ns
Male	ns

ANOVA: Analysis of variance, Pre: Pretreatment, Mon: Post-treatment month, ns: Not significant